golgin A6 family like 16, pseudogeneGenealiases: []
Q-omics provides the consensus-scored GOLGA6L16P profile across patient tissues and cancer cell-line models. GOLGA6L16P expression is associated with patient survival in 7 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, GOLGA6L16P is differentially expressed in 2, with the highest sampling consensus in LUSC. Additionally, GOLGA6L16P RNA expression shows 4,380 significant pathway-activity associations, with the highest sampling consensus in ESCA. Together, these results highlight LIHC, LUSC, and ESCA as cancer lineages where GOLGA6L16P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GOLGA6L16P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GOLGA6L16P survival associations across molecular data types. GOLGA6L16P RNA expression shows survival associations in the most cancer types (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GOLGA6L16P RNA expression–survival associations across cancer types. High GOLGA6L16P expression shows unfavorable associations in LIHC, THCA, KICH, PCPG and GBM, but favorable associations in ESCA. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .006). Together, the overview and detailed table identify LIHC as the clearest survival context for GOLGA6L16P RNA expression.
This table summarizes GOLGA6L16P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for GOLGA6L16P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GOLGA6L16P shows higher tumor expression in LUSC and PRAD. The LUSC box plot shows higher GOLGA6L16P RNA expression in tumor versus normal tissue (log2 FC = +0.036, t-test p = .027).
This table shows molecular features associated with GOLGA6L16P in patient tissues and cancer cell lines. In patient samples, GOLGA6L16P shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
